SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):August 6, 2003
ARADIGM CORPORATION
(Exact name of registrant as specified in its charter)
California
(State or other jurisdiction of incorporation)
| | | |
| 0-28402 | | 94-3133088 |
| (Commission File No.) | | (IRS Employer Identification No.) |
3929 Point Eden Way
Hayward, California 94545
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:(510) 265-9000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
TABLE OF CONTENTS
INFORMATION TO BE INCLUDED IN THE REPORT
Item 7. Exhibits.
| | | |
| Exhibit | | |
| Number | | Description |
| |
|
| 99.1 | | Transcript of call held on August 6, 2003. |
Item 9. Regulation FD Disclosure
On August 6, 2003, Aradigm Corporation (the “Company”) held a conference call to discuss the status of ongoing and future clinical trials and commercial scale-up preparations with regard to the Company’s AERx insulin Diabetes Management System. A transcript of the call is being furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | |
| | | | | ARADIGM CORPORATION |
| | | | | |
| Dated: August 11, 2003 | | By: | | /S/ THOMAS C. CHESTERMAN |
| | | | |
|
| | | | | Thomas C. Chesterman |
| | | | | |
| | | Title: | | Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
INDEX TO EXHIBITS
| | | |
| Exhibit | | |
| Number | | Description |
| |
|
| 99.1 | | Transcript of call held on August 6, 2003. |
